Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. uri icon

Overview

authors

publication date

  • July 21, 2025

Identity

Digital Object Identifier (DOI)

  • 10.1038/s41591-025-03895-1

PubMed ID

  • 40691367